Table 2.
The DMT medication of MS patients after 12 months and association between COVID-19 infection and DMT category.
| COVID-19 infection | Disease modifying treatment (DMT) | P-value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INF β 1a IM injection |
INF β 1a SC injection |
INF β 1b SC injection |
Glatiramer acetate | DMF | Teriflunomide | Fingolimod | Natalizumab | No DMT | Rituximab | Azathioprine | ||
| Positive (n = 25) | 5 (2.79%) | 5 (2.79%) | 1 (0.55%) | 1 (0.55%) | 2(1.11%) | 0 (0%) | 2 (1.11%) | 0 (0.00%) | 3 (1.67) | 5 (2.79%) | 1 (0.55%) | 0.190 |
| Negative (n = 177) | 32 (17.87%) | 16 (8.93%) | 9 (5.02%) | 12 (6.70%) | 25 (13.96) | 1 (0.55%) | 11 (6.14%) | 1 (0.55%) | 20 (11.17%) | 46 (25.69%) | 4 (2.23%) | |